)
Edge23 Jan 2026
Death, Taxes, and Garbage: The Story of WM
How Waste Management turned garbage into one of America's most stable business models through landfills, regulation, and nationwide scale.
Aligos Therapeutics
Aligos Therapeutics (ALGS) investor relations material
Aligos Therapeutics Jefferies London Healthcare Conference 2025 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Jefferies London Healthcare Conference 2025 summary17 Nov, 2025
Portfolio overview and pipeline updates
Lead program pevifoscorvir (pevi) targets hepatitis B, showing strong phase II progress and unique dual mechanisms of action.
Additional assets include ALG-009 (beta thyroid agonist for MASH), a pan-coronavirus protease inhibitor in phase II, and preclinical antisense oligonucleotides for HBV and HDV.
Pevi is the first capsid assembly modulator in the clinic to demonstrate effects on cccDNA, a key viral reservoir.
Phase II global study of pevi is ongoing, with interim analysis expected early next year and top-line data in 2027.
ALG-009 shows superior potency and pharmacokinetics compared to competitors, with phase II-B readiness and potential for accelerated development.
Clinical results and competitive positioning
Pevi monotherapy achieves rapid and sustained HBV DNA suppression, outperforming standard nucleoside analogs in both E positive and E negative patients.
No drug resistance observed with pevi, even against variants resistant to other capsid assembly modulators, enabling monotherapy and regulatory alignment.
Pevi reduces HBV surface and E antigens, indicating cccDNA suppression; antigen reductions are maintained after therapy cessation.
Safety profile is favorable, with no discontinuations due to adverse events and only transient ALT elevations.
Pevi is positioned as a future standard of care for chronic HBV suppression and as a combination partner for functional cure regimens.
Market need and future milestones
Chronic HBV remains a major global health issue, with current therapies leaving most patients at risk for liver disease and cancer.
Pevi addresses the unmet need for broader and deeper viral suppression, especially for patients ineligible for functional cure therapies.
Upcoming milestones include interim phase II analysis (early next year) and primary endpoint readout in 2027.
ALG-009 demonstrated nearly double the fat reduction of a leading competitor in MASH and may enhance weight loss when combined with incretins.
Full data on ALG-009’s metabolic effects to be presented at an upcoming Hep-DART meeting.
Pevi's resistance profile and implications
Pevi's market positioning for HBV patients
ALG-009's differentiation in MASH and obesity
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Aligos Therapeutics earnings date
Q4 20259 Mar, 2026
Aligos Therapeutics
Next Aligos Therapeutics earnings date
Q4 20259 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Aligos Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in the development of novel therapeutics to address unmet medical needs in viral and liver diseases. The company's development pipeline includes drug candidates for the treatment of conditions such as non-alcoholic steatohepatitis (NASH), chronic hepatitis B (CHB), and coronavirus. Aligos Therapeutics utilizes a combination of small molecule and oligonucleotide platforms to create pharmacologically optimized drug candidates aimed at improving treatment outcomes in these diseases. The company is headquartered in South San Francisco, California, and its shares are listed on the Nasdaq.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage